Cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolemia with realistic cascade screening acceptance rates and use of high-cost drugs

Abstract excerpt

<h4>Background</h4> Cascade screening (CS) for familial hypercholesterolemia (FH) is cost-effective in many countries. However, most existing economic evaluation studies (i) ignored or overstated first-degree relative (FDR) participation rate (as 60-100%), (ii) did not consider novel and expensive therapies, e.g. PCSK9 inhibitors (PCSK9i), (iii) were conducted outside of Asia. In Singapore, FDR participation rate...

Topics

Open a Topic to create a Post that cites this publication.

• Anticholesteremic Agents
• Decision Trees
• Drug Costs
• Health Care Costs
• Models, Economic
• Quality-Adjusted Life Years
• Serine Proteinase Inhibitors
• Singapore

Identifiers and source

Literature Corpus work

475bcc82-219d-5357-8de7-f9b4903ac056

DOI

10.1101/2025.01.17.25320710